NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
NR 565 / NR565 Advanced Pharmacology Final Exam
Review
More Than 100 Questions & Answers | Rated A | Latest 2026/2027 | Chamberlain
Aligned with Chamberlain University NR565 Course Syllabus, AACN Essentials of Master’s Education, and
Advanced Practice Pharmacotherapeutics Standards
Total Questions 130 Multiple Choice (A–D)
Cognitive Levels 20% Recall | 50% Application | 30% Analysis
Question Style 75% Scenario-based | 25% Direct Knowledge
Sections 11 (PK/PD → Drug Interactions & Monitoring)
Special Inclusions 15 CYP450/interactions, 10 special populations, 10 monitoring/ADR
This comprehensive final exam review has been constructed to mirror the depth and breadth of the Chamberlain
University NR 565 Advanced Pharmacology course for the 2026/2027 academic cycle. Each item has been calibrated
to the AACN Essentials of Master’s Education for Advanced Practice Nursing and to advanced
pharmacotherapeutics competencies expected of the graduate-prepared nurse practitioner. Distractors reflect the most
common prescribing errors, drug-interaction oversights, monitoring misinterpretations, and contraindication
confusion observed in clinical practice and on standardized advanced pharmacology examinations. Read each stem
carefully, identify the pharmacologic principle being tested, and use the rationale to reinforce the underlying
mechanism, monitoring parameter, or prescribing consideration that justifies the best answer.
Section 1: Pharmacokinetics & Pharmacodynamics
Chamberlain University | Page 1 | NR 565 Final Exam Bank
,NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q1: A 68-year-old male with hepatic cirrhosis is started on a drug that undergoes extensive first-pass
metabolism when given orally. Which pharmacokinetic consequence should the prescriber most
anticipate?
A. Bioavailability will decrease; increase the oral dose to compensate.
B. First-pass effect will increase; switch to an intravenous route.
C. Bioavailability will increase; reduce the oral dose or extend the dosing interval. *[CORRECT]*
D. Hepatic clearance is unchanged; no dose adjustment is needed.
Correct Answer: C
Rationale: In hepatic cirrhosis, shunting of portal blood away from hepatocytes and reduced enzymatic capacity
markedly decrease first-pass metabolism, increasing the oral bioavailability of high-extraction drugs such as
propranolol, verapamil, and morphine. The NR 565 PK curriculum requires reducing the oral dose or extending the
dosing interval to avoid supratherapeutic exposure. Increasing the dose (A) would worsen toxicity; IV conversion (B)
is not automatically required.
Q2: A patient has a steady-state drug level above the therapeutic range despite a standard maintenance
dose. Albumin is 2.0 g/dL. The drug is highly protein-bound. Which mechanism best explains the
elevated free drug concentration?
A. Increased hepatic metabolism of the bound fraction.
B. Decreased protein binding shifting bound drug to free drug. *[CORRECT]*
C. Enhanced renal tubular secretion of metabolites.
D. Reduced volume of distribution causing accumulation.
Correct Answer: B
Rationale: Highly protein-bound drugs (warfarin, phenytoin, diazepam) rely on albumin for transport; when albumin
falls below ~2.5 g/dL, binding sites are reduced and the free (active) fraction rises substantially. The NR 565
curriculum stresses monitoring free drug levels in hypoalbuminemia. The other options misattribute the mechanism or
describe downstream consequences.
Q3: A drug has a half-life of 12 hours and is administered once daily. Approximately how many doses are
required to reach steady-state plasma concentration?
A. 2 doses; steady state occurs after one half-life.
B. 3 doses; steady state occurs after two half-lives.
C. 5 doses; steady state occurs after approximately 4–5 half-lives. *[CORRECT]*
D. 10 doses; steady state occurs after ten half-lives.
Correct Answer: C
Rationale: Steady state is achieved after roughly 4–5 half-lives regardless of dosing frequency, because elimination
rate rises as accumulation occurs until input equals output. For a 12-hour half-life given once daily (24-hour interval),
about 5 doses are needed. The NR 565 PK framework uses this principle to time trough levels and to decide when a
loading dose is warranted.
Chamberlain University | Page 2 | NR 565 Final Exam Bank
,NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q4: A 55-year-old receiving IV phenytoin for status epilepticus develops nystagmus, ataxia, and
confusion. The phenytoin level returns at 24 mcg/mL (therapeutic 10–20). What pharmacokinetic
property of phenytoin best explains toxicity within the "therapeutic" range?
A. Linear (first-order) elimination at all concentrations.
B. Michaelis-Menten (saturable) metabolism causing nonlinear kinetics. *[CORRECT]*
C. High renal clearance that varies with urine pH.
D. Extensive first-pass effect reducing oral bioavailability.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (capacity-limited, zero-order at high concentration) metabolism;
once hepatic enzymes are saturated, small dose increases produce disproportionate plasma concentration rises, so
toxicity can occur just above the therapeutic range. The NR 565 PK module requires level-guided titration and
recognition of nonlinear kinetics. The other options misdescribe first-order behavior, urinary clearance, or first-pass
effect.
Q5: A provider is comparing two beta-1 selective blockers. Drug X has an EC50 of 2 mg and a maximum
effect of 80% receptor occupancy; Drug Y has an EC50 of 8 mg and a maximum effect of 80% receptor
occupancy. Which statement is correct?
A. Drug X is more potent; efficacy is equal. *[CORRECT]*
B. Drug X is more efficacious; potency is equal.
C. Drug Y is more potent; efficacy is equal.
D. Drug Y is more efficacious; potency is equal.
Correct Answer: A
Rationale: Potency is reflected by EC50 — a lower EC50 means less drug is needed to achieve 50% of maximal
effect, so Drug X is more potent. Efficacy is reflected by Emax; both reach 80% maximal effect, so efficacy is equal.
The NR 565 pharmacodynamics module stresses that potency affects dose selection but not the maximum achievable
response.
Q6: A patient is started on a full agonist at the mu-opioid receptor. Two weeks later, naloxone is
administered for respiratory depression. Which pharmacodynamic term best describes naloxone’s
receptor activity?
A. Partial agonist with low efficacy.
B. Competitive antagonist with zero intrinsic activity. *[CORRECT]*
C. Inverse agonist reducing constitutive receptor activity.
D. Noncompetitive antagonist producing irreversible blockade.
Correct Answer: B
Rationale: Naloxone binds the mu-opioid receptor with high affinity but zero intrinsic activity, displacing the agonist
and producing competitive, reversible antagonism. The NR 565 receptor-theory framework contrasts full agonists,
partial agonists, competitive (surmountable) antagonists, and noncompetitive (insurmountable) antagonists. Naloxone
is the prototypic competitive antagonist, which is why escalating opioid doses can overcome its blockade.
Chamberlain University | Page 3 | NR 565 Final Exam Bank
, NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q7: A drug has a narrow therapeutic index (TI). Which monitoring and prescribing implication is most
consistent with this property?
A. TI = TD50/ED50; a narrow TI means dose individualization and serum drug monitoring are
required. *[CORRECT]*
B. TI = ED50/TD50; a narrow TI means the drug is safe at any therapeutic dose.
C. A narrow TI indicates the drug is highly selective for receptors.
D. A narrow TI indicates that drug interactions are clinically insignificant.
Correct Answer: A
Rationale: Therapeutic index is classically TD50/ED50; a narrow TI (warfarin, digoxin, lithium, aminoglycosides)
means toxic and therapeutic doses are close, requiring individualized dosing, serum-level monitoring, and vigilant
interaction screening. The NR 565 curriculum requires mastery of TI for high-risk drugs. The other options reverse the
ratio or misinterpret selectivity and interaction risk.
Q8: A 72-year-old female with CKD stage 4 (eGFR 22 mL/min) is prescribed gentamicin for a
gram-negative UTI. Which pharmacokinetic parameter must be adjusted, and what is the primary
rationale?
A. Absorption; decreased gut motility in CKD delays onset.
B. Distribution; increased total body water raises volume of distribution.
C. Excretion; reduced GFR prolongs half-life and increases accumulation risk. *[CORRECT]*
D. Metabolism; reduced hepatic CYP3A4 activity slows biotransformation.
Correct Answer: C
Rationale: Gentamicin is almost entirely eliminated by glomerular filtration; in advanced CKD, half-life prolongs
dramatically, increasing the risk of nephrotoxicity and ototoxicity. The NR 565 curriculum teaches renal dose
adjustment by GFR, extended dosing intervals, and therapeutic drug monitoring of peak and trough levels. The other
options misidentify the affected PK phase.
Q9: A patient receives a loading dose of a drug with a half-life of 60 hours to rapidly achieve therapeutic
levels. Which pharmacokinetic principle justifies the loading dose, and what formula is most commonly
applied?
A. Loading dose = (Css × Vd) / F, used when steady state would be delayed by long half-life.
*[CORRECT]*
B. Loading dose = (Clearance × Css) / F, used only in renal failure.
C. Loading dose = (F × Dose) / Vd, used for high-extraction drugs.
D. Loading dose = Css / Vd, used when bioavailability is unknown.
Correct Answer: A
Rationale: For drugs with long half-lives (amiodarone, digoxin, phenytoin), waiting 4–5 half-lives to reach steady
state is clinically unacceptable, so a loading dose = (Css × Vd) / F is administered to fill the volume of distribution
rapidly. The NR 565 curriculum integrates loading and maintenance dosing concepts with therapeutic drug monitoring.
The other options misstate the formula or the clinical rationale.
Chamberlain University | Page 4 | NR 565 Final Exam Bank
NR 565 / NR565 Advanced Pharmacology Final Exam
Review
More Than 100 Questions & Answers | Rated A | Latest 2026/2027 | Chamberlain
Aligned with Chamberlain University NR565 Course Syllabus, AACN Essentials of Master’s Education, and
Advanced Practice Pharmacotherapeutics Standards
Total Questions 130 Multiple Choice (A–D)
Cognitive Levels 20% Recall | 50% Application | 30% Analysis
Question Style 75% Scenario-based | 25% Direct Knowledge
Sections 11 (PK/PD → Drug Interactions & Monitoring)
Special Inclusions 15 CYP450/interactions, 10 special populations, 10 monitoring/ADR
This comprehensive final exam review has been constructed to mirror the depth and breadth of the Chamberlain
University NR 565 Advanced Pharmacology course for the 2026/2027 academic cycle. Each item has been calibrated
to the AACN Essentials of Master’s Education for Advanced Practice Nursing and to advanced
pharmacotherapeutics competencies expected of the graduate-prepared nurse practitioner. Distractors reflect the most
common prescribing errors, drug-interaction oversights, monitoring misinterpretations, and contraindication
confusion observed in clinical practice and on standardized advanced pharmacology examinations. Read each stem
carefully, identify the pharmacologic principle being tested, and use the rationale to reinforce the underlying
mechanism, monitoring parameter, or prescribing consideration that justifies the best answer.
Section 1: Pharmacokinetics & Pharmacodynamics
Chamberlain University | Page 1 | NR 565 Final Exam Bank
,NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q1: A 68-year-old male with hepatic cirrhosis is started on a drug that undergoes extensive first-pass
metabolism when given orally. Which pharmacokinetic consequence should the prescriber most
anticipate?
A. Bioavailability will decrease; increase the oral dose to compensate.
B. First-pass effect will increase; switch to an intravenous route.
C. Bioavailability will increase; reduce the oral dose or extend the dosing interval. *[CORRECT]*
D. Hepatic clearance is unchanged; no dose adjustment is needed.
Correct Answer: C
Rationale: In hepatic cirrhosis, shunting of portal blood away from hepatocytes and reduced enzymatic capacity
markedly decrease first-pass metabolism, increasing the oral bioavailability of high-extraction drugs such as
propranolol, verapamil, and morphine. The NR 565 PK curriculum requires reducing the oral dose or extending the
dosing interval to avoid supratherapeutic exposure. Increasing the dose (A) would worsen toxicity; IV conversion (B)
is not automatically required.
Q2: A patient has a steady-state drug level above the therapeutic range despite a standard maintenance
dose. Albumin is 2.0 g/dL. The drug is highly protein-bound. Which mechanism best explains the
elevated free drug concentration?
A. Increased hepatic metabolism of the bound fraction.
B. Decreased protein binding shifting bound drug to free drug. *[CORRECT]*
C. Enhanced renal tubular secretion of metabolites.
D. Reduced volume of distribution causing accumulation.
Correct Answer: B
Rationale: Highly protein-bound drugs (warfarin, phenytoin, diazepam) rely on albumin for transport; when albumin
falls below ~2.5 g/dL, binding sites are reduced and the free (active) fraction rises substantially. The NR 565
curriculum stresses monitoring free drug levels in hypoalbuminemia. The other options misattribute the mechanism or
describe downstream consequences.
Q3: A drug has a half-life of 12 hours and is administered once daily. Approximately how many doses are
required to reach steady-state plasma concentration?
A. 2 doses; steady state occurs after one half-life.
B. 3 doses; steady state occurs after two half-lives.
C. 5 doses; steady state occurs after approximately 4–5 half-lives. *[CORRECT]*
D. 10 doses; steady state occurs after ten half-lives.
Correct Answer: C
Rationale: Steady state is achieved after roughly 4–5 half-lives regardless of dosing frequency, because elimination
rate rises as accumulation occurs until input equals output. For a 12-hour half-life given once daily (24-hour interval),
about 5 doses are needed. The NR 565 PK framework uses this principle to time trough levels and to decide when a
loading dose is warranted.
Chamberlain University | Page 2 | NR 565 Final Exam Bank
,NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q4: A 55-year-old receiving IV phenytoin for status epilepticus develops nystagmus, ataxia, and
confusion. The phenytoin level returns at 24 mcg/mL (therapeutic 10–20). What pharmacokinetic
property of phenytoin best explains toxicity within the "therapeutic" range?
A. Linear (first-order) elimination at all concentrations.
B. Michaelis-Menten (saturable) metabolism causing nonlinear kinetics. *[CORRECT]*
C. High renal clearance that varies with urine pH.
D. Extensive first-pass effect reducing oral bioavailability.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (capacity-limited, zero-order at high concentration) metabolism;
once hepatic enzymes are saturated, small dose increases produce disproportionate plasma concentration rises, so
toxicity can occur just above the therapeutic range. The NR 565 PK module requires level-guided titration and
recognition of nonlinear kinetics. The other options misdescribe first-order behavior, urinary clearance, or first-pass
effect.
Q5: A provider is comparing two beta-1 selective blockers. Drug X has an EC50 of 2 mg and a maximum
effect of 80% receptor occupancy; Drug Y has an EC50 of 8 mg and a maximum effect of 80% receptor
occupancy. Which statement is correct?
A. Drug X is more potent; efficacy is equal. *[CORRECT]*
B. Drug X is more efficacious; potency is equal.
C. Drug Y is more potent; efficacy is equal.
D. Drug Y is more efficacious; potency is equal.
Correct Answer: A
Rationale: Potency is reflected by EC50 — a lower EC50 means less drug is needed to achieve 50% of maximal
effect, so Drug X is more potent. Efficacy is reflected by Emax; both reach 80% maximal effect, so efficacy is equal.
The NR 565 pharmacodynamics module stresses that potency affects dose selection but not the maximum achievable
response.
Q6: A patient is started on a full agonist at the mu-opioid receptor. Two weeks later, naloxone is
administered for respiratory depression. Which pharmacodynamic term best describes naloxone’s
receptor activity?
A. Partial agonist with low efficacy.
B. Competitive antagonist with zero intrinsic activity. *[CORRECT]*
C. Inverse agonist reducing constitutive receptor activity.
D. Noncompetitive antagonist producing irreversible blockade.
Correct Answer: B
Rationale: Naloxone binds the mu-opioid receptor with high affinity but zero intrinsic activity, displacing the agonist
and producing competitive, reversible antagonism. The NR 565 receptor-theory framework contrasts full agonists,
partial agonists, competitive (surmountable) antagonists, and noncompetitive (insurmountable) antagonists. Naloxone
is the prototypic competitive antagonist, which is why escalating opioid doses can overcome its blockade.
Chamberlain University | Page 3 | NR 565 Final Exam Bank
, NR 565 — Advanced Pharmacology Final Exam Rated A | 130 Q&A | Latest 2026/2027
Q7: A drug has a narrow therapeutic index (TI). Which monitoring and prescribing implication is most
consistent with this property?
A. TI = TD50/ED50; a narrow TI means dose individualization and serum drug monitoring are
required. *[CORRECT]*
B. TI = ED50/TD50; a narrow TI means the drug is safe at any therapeutic dose.
C. A narrow TI indicates the drug is highly selective for receptors.
D. A narrow TI indicates that drug interactions are clinically insignificant.
Correct Answer: A
Rationale: Therapeutic index is classically TD50/ED50; a narrow TI (warfarin, digoxin, lithium, aminoglycosides)
means toxic and therapeutic doses are close, requiring individualized dosing, serum-level monitoring, and vigilant
interaction screening. The NR 565 curriculum requires mastery of TI for high-risk drugs. The other options reverse the
ratio or misinterpret selectivity and interaction risk.
Q8: A 72-year-old female with CKD stage 4 (eGFR 22 mL/min) is prescribed gentamicin for a
gram-negative UTI. Which pharmacokinetic parameter must be adjusted, and what is the primary
rationale?
A. Absorption; decreased gut motility in CKD delays onset.
B. Distribution; increased total body water raises volume of distribution.
C. Excretion; reduced GFR prolongs half-life and increases accumulation risk. *[CORRECT]*
D. Metabolism; reduced hepatic CYP3A4 activity slows biotransformation.
Correct Answer: C
Rationale: Gentamicin is almost entirely eliminated by glomerular filtration; in advanced CKD, half-life prolongs
dramatically, increasing the risk of nephrotoxicity and ototoxicity. The NR 565 curriculum teaches renal dose
adjustment by GFR, extended dosing intervals, and therapeutic drug monitoring of peak and trough levels. The other
options misidentify the affected PK phase.
Q9: A patient receives a loading dose of a drug with a half-life of 60 hours to rapidly achieve therapeutic
levels. Which pharmacokinetic principle justifies the loading dose, and what formula is most commonly
applied?
A. Loading dose = (Css × Vd) / F, used when steady state would be delayed by long half-life.
*[CORRECT]*
B. Loading dose = (Clearance × Css) / F, used only in renal failure.
C. Loading dose = (F × Dose) / Vd, used for high-extraction drugs.
D. Loading dose = Css / Vd, used when bioavailability is unknown.
Correct Answer: A
Rationale: For drugs with long half-lives (amiodarone, digoxin, phenytoin), waiting 4–5 half-lives to reach steady
state is clinically unacceptable, so a loading dose = (Css × Vd) / F is administered to fill the volume of distribution
rapidly. The NR 565 curriculum integrates loading and maintenance dosing concepts with therapeutic drug monitoring.
The other options misstate the formula or the clinical rationale.
Chamberlain University | Page 4 | NR 565 Final Exam Bank
